New experimental therapy could significantly reduce bad cholesterol

Dr. Craig Basman, an interventional cardiologist, joins Fox & Friends to discuss a new experimental therapy showing promising results in reducing bad cholesterol by up to 62%.

Dr. Craig Basman, an interventional cardiologist, discusses a new gene-editing therapy, VERVE-102, which significantly reduces bad cholesterol levels. This single-dose treatment alters DNA in the liver, showing a 62% drop in LDL cholesterol. While still in phase one trials, it holds immense promise for preventing heart disease and related cardiovascular events like stroke.